Sökresultat - Gautam Borthakur

Förfina resultatet
  1. 1
    Core binding factor acute myelogenous leukemia-2021 treatment algorithm

    Core binding factor acute myelogenous leukemia-2021 treatment algorithm av Gautam Borthakur, Hagop M. Kantarjian

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  2. 2
    Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia

    Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia av Sujan Piya, Michael Andreeff, Gautam Borthakur

    Publicerad 2016
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  3. 3
    Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies

    Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies av Adishwar Rao, Akriti Agrawal, Gautam Borthakur, Venkata Lokesh Battula, Abhishek Maiti

    Publicerad 2024
    Hämta fulltext Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  4. 4
    Erythroleukemia-historical perspectives and recent advances in diagnosis and management

    Erythroleukemia-historical perspectives and recent advances in diagnosis and management av Prajwal Boddu, Christopher B. Benton, Wei Wang, Gautam Borthakur, Joseph D. Khoury, Naveen Pemmaraju

    Publicerad 2017
    Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  5. 5
    Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

    Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis av Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Zeev Estrov, Gautam Borthakur, Jorge E. Cortés, Srđan Verstovšek

    Publicerad 2012
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  6. 6
    Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

    Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia av Ahmed Aribi, Gautam Borthakur, Farhad Ravandi, Jianqin Shan, Jan Davisson, Jorge E. Cortés, Hagop M. Kantarjian

    Publicerad 2007
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  7. 7
    Localization of the Adhesion Receptor Glycoprotein Ib-IX-V Complex to Lipid Rafts Is Required for Platelet Adhesion and Activation

    Localization of the Adhesion Receptor Glycoprotein Ib-IX-V Complex to Lipid Rafts Is Required for Platelet Adhesion and Activation av Corie N. Shrimpton, Gautam Borthakur, Susana Larrucea, Miguel A. Crúz, Jing-fei Dong, José A. López

    Publicerad 2002
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  8. 8
    Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia

    Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia av Alison Gardner, Gloria Mattiuzzi, Stefan Faderl, Gautam Borthakur, Guillermo Garcia‐Manero, Sherry Pierce, Mark Brandt, Elihu H. Estey

    Publicerad 2008
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  9. 9
    Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

    Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges av Nicholas J. Short, Marina Konopleva, Tapan M. Kadia, Gautam Borthakur, Farhad Ravandi, Courtney D. DiNardo, Naval Daver

    Publicerad 2020
    Hämta fulltext
    Revisão
    Lägg till i favoriter
    Sparad:
  10. 10
    Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

    Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance av Dushyant Verma, Hagop M. Kantarjian, Dan Jones, Rajyalakshmi Luthra, Gautam Borthakur, Srđan Verstovšek, Mary Beth Rios, Jorge E. Cortés

    Publicerad 2009
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  11. 11
    Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia

    Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chron... av Constantine S. Tam, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Gautam Borthakur, Susan O’Brien, Farhad Ravandi, Jenny Shan, Jorge E. Cortés

    Publicerad 2008
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  12. 12
    Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

    Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine av Gautam Borthakur, Samih El Ahdab, Farhad Ravandi, Stefan Faderl, Alessandra Ferrajoli, Beth Newman, Jean–Pierre J. Issa, Hagop M. Kantarjian

    Publicerad 2008
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  13. 13
    The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations

    The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations av Weiguo Zhang, Gautam Borthakur, Gao Chen, Ye Chen, Hong Mu, Vivian Ruvolo, K. Nomoto, Nanding Zhao, Marina Konopleva, Michael Andreeff

    Publicerad 2016
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  14. 14
    Reversal of Acquired Drug Resistance in <i>FLT3</i>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies

    Reversal of Acquired Drug Resistance in <i>FLT3</i>-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies av Weiguo Zhang, Gao Chen, Marina Konopleva, Ye Chen, Rodrigo Jácamo, Gautam Borthakur, Jorge E. Cortés, Farhad Ravandi, Abhijit Ramachandran, Michael Andreeff

    Publicerad 2014
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  15. 15
    De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

    De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017 av Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Courtney D. DiNardo, Nicholas J. Short, Gautam Borthakur, Elias Jabbour, Hagop M. Kantarjian

    Publicerad 2021
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  16. 16
    Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

    Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy av Dushyant Verma, Hagop M. Kantarjian, Jianqin Shan, Susan O’Brien, Zeev Estrov, Guillermo Garcia‐Manero, Charles Koller, Gautam Borthakur, Jorge E. Cortés

    Publicerad 2010
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  17. 17
    Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy

    Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy av Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Megan Breeden, Guillermo Garcia‐Manero, Susan O’Brien, Farhad Ravandi, Gautam Borthakur, Jorge E. Cortés

    Publicerad 2008
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  18. 18
    Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients

    Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients av Peter P. Ruvolo, Yi Hua Qui, Kevin R. Coombes, Ningyan Zhang, Vivian Ruvolo, Gautam Borthakur, Marina Konopleva, Michael Andreeff, Steven M. Kornblau

    Publicerad 2011
    Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  19. 19
    Prognostic value of <i>FLT3</i> mutations among different cytogenetic subgroups in acute myeloid leukemia

    Prognostic value of <i>FLT3</i> mutations among different cytogenetic subgroups in acute myeloid leukemia av Fabio P S Santos, Dan Jones, Wei Qiao, Jorge E. Cortés, Farhad Ravandi, Elihu E. Estey, Dushyant Verma, Hagop M. Kantarjian, Gautam Borthakur

    Publicerad 2010
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:
  20. 20
    Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

    Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment av Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jorge E. Cortés, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey

    Publicerad 2011
    Hämta fulltext Hämta fulltext
    Artigo
    Lägg till i favoriter
    Sparad:

Sökverktyg: